Tags : INAD

Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal

Vartika Singh March 14, 2019

Shots: The EMA’s ODD is based on P-II/III study assessing RT001 in patients with INAD, a neurodegeneration associated with PLA2G6 EMA’s ODD is granted to the drug offering treatments for […]readmore

Tags : INAD

Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : INAD

﻿Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Retrotope’s RT001 Receives EMA’s Orphan Drug Designation for Infantile Neuroaxonal